The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Targeted therapies for metastatic colorectal cancer (mCRC): A systematic review of cost-effectiveness (CE).
Tanya G. Bentley
Research Funding - Bristol-Myers Squibb
Michael Samuel Broder
Research Funding - Bristol-Myers Squibb
Lopamudra Das
Research Funding - Bristol-Myers Squibb
Jesse Ortendahl
Research Funding - Bristol-Myers Squibb
Yun Su
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Samuel Wagner
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb